Back to search

Aristotle University Of Thessaloniki (AUTH)

Η φαρμακοκινητική της μοξιφλοξασίνης σε ασθενείς με υπεζωκοτική συλλογή

Abstract

dc:description

Respiratory fluoroquinolones such as moxifloxacin or levofloxacin are recommended as initial empiric antibiotic therapy both for hospitalized patients with severe and non-severe CAP and for those with HAP or ventilator-associated pneumonia without known risk factors for multidrug-resistant pathogens and early onset. Moxifloxacin is widely used in the treatment of community-acquired pneumonia and pleural effusion due to its broad antimicrobial activity against Gram-positive and Gram-negative bacteria, including anaerobes.The aim of this study was to evaluate the pharmacokinetics and penetration of moxifloxacin in patients with various types of pleural effusion. Twelve patients with empyema/parapneumonic effusion (group A) (56.2 ± 18.6 years) and twelve patients with malignant pleural effusion (group B) (70.9 ± 12.2 years), were enrolled in the study. A single dose pharmacokinetic study was performed after intravenous administration of 400 mg MXF. Serial plasma (PL) and pleural fluid (PF) samples were collected during a 24h time interval after drug administration. MXF concentration in (PL) and (PF) was determined by HPLC-fluorescence detector and main pharmacokinetic parameters were estimated using the WinNonlin software program. Penetration of MXF in PF was determined by the AUC24 PF/AUC24 PL ratio. There were no statistically significant differences between two groups in PL pharmacokinetics despite large interindividual variability in volume of distribution, clearance and elimination half-life. The mean peak concentrations in plasma were 4.64±0.68 for group A and 4.28±0.69 mg/L for group B, respectively and were achieved by the end of drug infusion. The mean concentrations in plasma at 24 hours (CtroughPL) were 0.37±0.13 for group A and 0.39±0.07 mg/L for group B. A large variability was observed in the pharmacokinetic data, for both groups, especially in the volume of distribution (Vd), which ranged from 82.66 to 310.95 L, although their mean value was similar (165.12 for group A vs 155.22 L for group B). Similarly, clearance (CL) ranged from 6.82 to 19.10 L/h, and the elimination half-life (t1/2) was as short as 3.84 h and as long as 36.20 h. In both groups a similar AUC24PL was observed (28.39±5.47 for group A vs. 28.06±4.37 mg/L*h for group B). In PF, CmaxPF in patients with empyema/PPE was 2.23±1.31 mg/L, and it was detected 7.50±2.39 h after the initiation of the infusion. In patients with malignant effusion, CmaxPF was 2.96±1.45 mg/L, but it was observed significantly earlier at 3.58±1.38 h (p<0.001). Both groups revealed a similar on-site drug exposure as expressed by the AUC24PF,(31.83±23.52 vs 32.81±12.66 mg/L*h). Penetration of MXF into PF was similarly good in both patient groups (1.11±0.74 vs 1.17±0.39) and did not differ according to the type of pleural effusion. The equilibration of MXF concentration between plasma and pleural fluid occurred at 5 hours in patients with empyema/parapneumonic effusion, versus 3 hours in those with malignant effusion. The pharmacodynamic study of moxifloxacin was performed by the use of local microbiological data of our hospital and the MIC’s of common pathogens of the pleural space. The parmacodynamic target of fAUC24/MIC > 30 was attained in all patients, for gram positive pathogens such as S.pneumoniae και S.aureus, in plasma and pleural fluid. For gram negative pathogens, the parmacodynamic target of AUC24/MIC>125 was attained for H. influenzae and M. catarrhalis strains, in all patients, in plasma and pleura fluid, but not for P. aeruginosa strains. Similarly, the pharmacodynamic target of Cmax/MIC > 8-10 was easily attained in plasma, in all patients, for S.pneumoniae, S.aureus, H. influenzae and M. catarrhalis strains, but only in 9 out of 12 patients for P. aeruginosa strains. In pleural fluid, the same target was attained in all patients for H. influenzae and M. catarrhalis strains, but only in 7 out of 12 patients for S.pneumoniae and S.aureus strains and only in one patient for P. aeruginosa strain.The results of the present study support the wide empirical use of MXF in the treatment of parapneumonic effusion and empyema providing evidence, for the first time in actual clinical conditions that MXF sufficiently penetrates into the pleural space and exhibits a favorable pharmacokinetic profile regardless of pleural fluid origin. In addition, this study is highlighting the need for careful use of moxifloxacin against pathogens that present high MIC’s but still reported as sensitive by the microbiology laboratory, because its pharmacodynamic exposure may be insufficient, leading to therapeutic failure with increased pressure of resistant strains selection.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2014

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Chatzika, Kalliopi
  • Χατζίκα, Καλλιόπη

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/34648

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Chatzika, Kalliopi; Χατζίκα, Καλλιόπη. Η φαρμακοκινητική της μοξιφλοξασίνης σε ασθενείς με υπεζωκοτική συλλογή. Aristotle University Of Thessaloniki (AUTH), 2014. http://hdl.handle.net/10442/hedi/34648